AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

被引：77

作者：

Karlowsky, James A. ^{[1
]}

Kaplan, Nachum ^{[2
]}

Hafkin, Barry ^{[2
]}

Hoban, Daryl J. ^{[1
]}

Zhanel, George G. ^{[1
]}

机构：

[1] Univ Manitoba, Fac Med, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada

[2] Affinium Pharmaceut Inc, Toronto, ON, Canada

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2009年 / 53卷 / 08期

关键词：

DISCOVERY; TRICLOSAN; AUREUS;

D O I：

10.1128/AAC.00400-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

AFN-1252, a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus aureus (n = 502) and Staphylococcus epidermidis (n = 51) tested, including methicillin (meticillin)-resistant isolates, at concentrations of <= 0.12 mu g/ml. In contrast, AFN-1252 was inactive (MIC90, >4 mu g/ml) against clinical isolates of Streptococcus pneumoniae, beta-hemolytic streptococci, Enterococcus spp., Enterobacteriaceae, nonfermentative gram-negative bacilli, and Moraxella catarrhalis. These data support the continued development of AFN-1252 for the treatment of patients with resistant staphylococcal infections.

引用

页码：3544 / 3548

页数：5

共 10 条

[1] Bacterial fatty acid biosynthesis: Targets for antibacterial drug discovery [J].

Campbell, JW ;

Cronan, JE .

ANNUAL REVIEW OF MICROBIOLOGY, 2001, 55 :305-332

[2]

*CLIN LAB STAND I, 2007, M100S17 CLIN LAB S S, V27

[3]

*CLIN LAB STAND I, 2006, M7 A7 APPR STAND

[4] Microbiology - A triclosan-resistant bacterial enzyme [J].

Heath, RJ ;

Rock, CO .

NATURE, 2000, 406 (6792) :145-146

[5] Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics [J].

Heath, RJ ;

White, SW ;

Rock, CO .

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2002, 58 (06) :695-703

[6]

Kaplan N, 2008, 48 INT C ANT AG CHEM

[7] In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis [J].

Karlowsky, James A. ;

Laing, Nancy M. ;

Baudry, Trish ;

Kaplan, Nachum ;

Vaughan, David ;

Hoban, Daryl J. ;

Zhanel, George G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1580-1581

[8] Discovery of a novel and potent class of fabI-directed antibacterial agents [J].

Payne, DJ ;

Miller, WH ;

Berry, V ;

Brosky, J ;

Burgess, WJ ;

Chen, E ;

DeWolf, WE ;

Fosberry, AP ;

Greenwood, R ;

Head, MS ;

Heerding, DA ;

Janson, CA ;

Jaworski, DD ;

Keller, PM ;

Manley, PJ ;

Moore, TD ;

Newlander, KA ;

Pearson, S ;

Polizzi, BJ ;

Qiu, XY ;

Rittenhouse, SF ;

Slater-Radosti, C ;

Salyers, KL ;

Seefeld, MA ;

Smyth, MG ;

Takata, DT ;

Uzinskas, IN ;

Vaidya, K ;

Wallis, NG ;

Winram, SB ;

Yuan, CCK ;

Huffman, WF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (10) :3118-3124

[9] Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus [J].

Slater-Radosti, C ;

Van Aller, G ;

Greenwood, R ;

Nicholas, R ;

Keller, PM ;

DeWolf, WE ;

Fan, F ;

Payne, DJ ;

Jaworski, DD .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (01) :1-6

[10]

Weiss W. J., 2008, 48 INT C ANT AG CHEM

← 1 →